Trial Profile
A Phase 1 Study of Nivolumab (BMS-936558) Plus Sunitinib, Pazopanib or Ipilimumab in Subjects With Metastatic Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 07 Dec 2021
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary) ; Ipilimumab; Pazopanib; Sunitinib
- Indications Renal cell carcinoma
- Focus Adverse reactions
- Acronyms CheckMate 016; CheckMate016
- Sponsors Bristol-Myers Squibb
- 30 Nov 2021 Status changed from active, no longer recruiting to completed.
- 27 Sep 2019 Planned End Date changed from 15 Aug 2019 to 30 Jun 2021.
- 12 Jun 2019 Planned End Date changed from 1 Jun 2018 to 15 Aug 2019.